Calculation of quality adjusted life years in the published literature: A review of methodology and transparency

Health Economics

Volumn 13, Issue 12, 2004, Pages 1203-1210

  Richardson, Gerald ^a   Manca, Andrea ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Economic evaluation; QALY estimation; Soct utility analysis

Indexed keywords

CALCULATION; COST UTILITY ANALYSIS; HEALTH CARE QUALITY; HEALTH ECONOMICS; HEALTH STATUS; HUMAN; METHODOLOGY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW;

COST-BENEFIT ANALYSIS; DATA INTERPRETATION, STATISTICAL; HEALTH STATUS INDICATORS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN;

EID: 10944224281     PISSN: 10579230     EISSN: None     Source Type: Journal    
DOI: 10.1002/hec.901     Document Type: Review

References (31)

1. Graves N, Walker D, Raine R, Hutchings A, Roberts JA. Cost data for individual patients included in clinical studies: no amount of statistical analysis can compensate for inadequate costing methods. Health Econ 2002; 11: 735-739.
2. Billingham LJ, Abrams KR, Jones DR. Methods for the analysis of quality of life and survival data in health technology assessment. Health Technol Assessment 1999; 3(10): 1-152.
3. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. Br Med J 1990 Jan 27; 300(6719): 230-235.
4. Morton V, Torgerson DJ. Effect of regression to the mean on decision making in health care. Br Med J 2003; 326: 1083-1084
5. Roberts C, Torgerson DJ. Baseline imbalance in randomised controlled trials. Br Med J 1999; 319: p. 185.
6. Briggs A, Clark T Wolstenholme J, Clarke P. Missing....presumed at random: cost-effectiveness of incomplete data. Health Econ 2003; 12(5): 377-392.
7. Norum J, Angelsen V. Chemotherapy in gastric cancer: an economic evaluation of the FAM (5-fluorouracil, adriamycin, mitomycin C) versus ELF (etoposide, leucovorin, 5-fluorouracil) regimens. J Chemotherapy 1995; 7(5): 455-459.
8. Griffin AD, Perry AS, Fleming DM. Cost-effectiveness of inhaled zanamivir in the treatment of influenza A and B in high risk patients. Pharmacoeconomics 2001; 19(3): 293-301.
9. Cheng AK, Rubin HR, Powe N, Mellon NK, Francis HW, Niparko JK. Cost-utility analysis of the cochlear implant in children. J Am Med Assoc 2000; 284: 850-856.
10. Guthrie E, Moorey J, Margison F et al. Cost-effectiveness of brief psychodynamic-interpersonal therapy in high utilizers of psychiatric services. Arch General Psychiatry 1999; 56(6): 519-526.
11. Lumsden MA, Twaddle S, Hawthorn R et al. A randomised comparison and economic evaluation of laparoscopic assisted hysterectomy and abdominal hysterectomy. Br J Obstet Gynaecol 2000; 107 11): 1386-1391.
12. Hurskainen R, Teperi J, Rissanen P et al. Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial. Lancet 2001; 357(9252): 273-277.
13. Torrance GW, Raynauld JP, Walker V et al. A prospective, randomized, pragmatic health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (part 2 of 2): economic results. Osteoarthritis Cartilage 2002; 10: 518-527.
14. MRC Laparoscopic Groin Hernia Trial Group. Cost utility of open versus laparoscopic groin hernia repair: results from a multi-centre randomized clinical trial. Br J Surgery 2001; 88(5): 653-661.
15. Campbell H, Tait S, Buxton M et al. A UK trial-based cost-utility analysis of transmyocardial laser revascularisation compared to continued medical therapy for treatment of refractory angina pectoris Eur J Cardio-Thoracic Surgery 2001; 20(2): 312-318.
16. Ekert H, Brewin T, Boey W, Davey P, Tilden D. Cost-utility analysis of recombinant factor VIIa (NovoSeven) in six children with long-standing inhibitors to factor VIII or IX. Haemophilia 2001; 7: 279-85.
17. Sculman KA, Buxton M, Glick H et al. Results of the economic evaluation of the FIRST study: a mulitnational prospective economic evaluation. Int J Technol Assessment Health Care 1996; 12(4): 698-713.
18. Mahoney EM, Jurkovitz CT, Chu H et al. for the TACTICS-TIMI 18 Investigators. Cost and cost-effectiveness of an early Invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. J Am Med Assoc 2002; 288: 1851-1858.
19. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999; 18: 341-364.
20. Briggs AH, O'Brien B. The Death of Costminimisation Analysis? Health Econ 2001; 10: 179-184.
21. Schulman KA, Dorsainvil D, Yabroff KR et al. Prospective econoic evaluation accompanying a trial of GM-CSF/IL-3 in patients undergoing autologous bone marrow transplantation for Hodgkins and non-Hodgkins lymphona. Bone Marrow Transplant 1998; 21 6): 607-614.
22. Richards DM, Irving MH. Cost utility analysis of home parenteral nutrition. Br J Surgery 1996; 83(9): 1226-1229.
23. van Enckevort PJ, TenVergert EM, Bonsel GJ et al. Technology assessment of the Dutch Lung Transplantation Program. International J Technol Assessment Health Care 1998; 14(2): 344-356.
24. Norum J, Vonen B, Olsen JA, Revhaug A. Adjuvant therapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma.: a cost-effectiveness analysis. Ann Oncol 1997; 8(1): 65-70.
25. Andersson A, Strom K, Brodin H et al. Domiciliary liquid oxygen versus concentrator treatment in chronic hypoxaemia: a cost utility analysis. Eur Respiratory J 1998; 12(6): 1284-1289.
26. Cohen DJ, Taira DA, Berezin R et al. Cost-effectiveness of coronary stenting in acute myocardial infarction: Results from the Stent PAMI Trial. Circulation 2001; 104: 3039-3045.
27. Uyl-de Groot CA, Hagenbeek A, Verdonck LF, Lowenberg B, Rutten FFH. Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate and high-grade malignant and non-Hodgkins Lymphoma (NHL). Bone Marrow Transplant 1995; 16: 463-470.
28. Grossman R, Mukherjee J, Vaughan D et al. A 1 year community based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 1998; 113(1): 131-141.
29. Nord E, Wisloff F, Hjorth M, Westin J. Cost utility analysis of melphalan plus prednisone with or without interferon-Alpha2b in newly diagnosed multiple myeloma: results from a randomised controlled trial. Pharmacoeconomics 1997; 12(1): 89-103
30. Hay J, LaBree L, Luo R et al. Cost-effectiveness of preventive occupational therapy for independent living adults. J Am Geriatrics Soc 2002; 50(8): 1381-1388.
31. Torrance G, Walker V, Grossman R et al. Economic evaluation of ciproflaxin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year. Pharmacoeconomics 1999; 16(5): 499-520.